» Articles » PMID: 28983605

LDHA Promotes Tumor Metastasis by Facilitating Epithelial‑mesenchymal Transition in Renal Cell Carcinoma

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2017 Oct 7
PMID 28983605
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have indicated that high expression of lactate dehydrogenase A (LDHA) exists in many human cancers. Recently, several reports showed that silencing or inhibition of LDHA could suppress metastasis of human cancer including renal cell carcinoma (RCC). However, the mechanism remains unknown. The role of LDHA in RCC migration and invasion was investigated using immunohistochemistry, western blotting, Transwell and scratch assays, and in vivo experiment. The influence of LDHA on the Warburg effect was also investigated by LDHA activity and lactate production assay. LDHA was overexpressed in RCC tissues and predicted a worse survival following renal resection. Correlation analysis demonstrated that LDHA was negatively correlated with E‑cadherin and positively with N‑cadherin. Experimentally, both in vivo and in vitro experiments found downregulation of LDHA suppressed RCC cells migration and invasion by inhibiting EMT. In addition, results indicated LDHA could promote the Warburg effect. Further research presented that the LDHA inhibitor, oxamate, suppressed tumor metastasis by inhibiting LDHA activity and EMT. These results demonstrated that LDHA mediates tumor metastasis by promoting EMT in RCC, suggesting that LDHA could be a promising therapeutic target for RCC therapy.

Citing Articles

Differential diagnosis of ovarian endometriosis cyst versus ovarian cystadenoma based on serum lactate dehydrogenase combined with CA-125 and CA19-9: A retrospective cohort study.

Su C, Yang J, Ding J, Ding H Medicine (Baltimore). 2024; 103(48):e40776.

PMID: 39612391 PMC: 11608665. DOI: 10.1097/MD.0000000000040776.


Lactate dehydrogenase A is a diagnostic biomarker associated with immune infiltration, m6A modification and ferroptosis in endometrial cancer.

Huang Y, Tang W, Chen L Front Oncol. 2024; 14:1458344.

PMID: 39582531 PMC: 11581964. DOI: 10.3389/fonc.2024.1458344.


Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.

Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.

PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.


Advancements in research on lactate dehydrogenase A in urinary system tumors.

Zhuo Z, Wang Y, Xu Y BMC Urol. 2024; 24(1):187.

PMID: 39215270 PMC: 11363645. DOI: 10.1186/s12894-024-01580-y.


Development of human lactate dehydrogenase a inhibitors: high-throughput screening, molecular dynamics simulation and enzyme activity assay.

Shu Y, Yue J, Li Y, Yin Y, Wang J, Li T J Comput Aided Mol Des. 2024; 38(1):28.

PMID: 39123063 DOI: 10.1007/s10822-024-00568-y.